Aerovate Therapeutics, Inc.
AVTE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,713,025 | $2,666,843 | $2,546,332 | $2,653,670 |
| - Cash | $50,106 | $220,942 | $44,220 | $33,751 |
| + Debt | $747 | $792 | $312 | $417 |
| Enterprise Value | $3,663,666 | $2,446,693 | $2,502,424 | $2,620,336 |
| Revenue | $0 | $0 | $0 | $112 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $56 |
| % Margin | – | – | – | 50% |
| EBITDA | -$25,175 | -$27,778 | -$3,387 | -$6,395 |
| % Margin | – | – | – | -5,709.8% |
| Net Income | -$25,175 | -$32,134 | -$2,518 | -$5,430 |
| % Margin | – | – | – | -4,848.2% |
| EPS Diluted | -482.25 | -863.46 | -0.09 | -0.19 |
| % Growth | 44.1% | -959,300% | 52.6% | – |
| Operating Cash Flow | -$22,124 | -$36,535 | -$2,381 | -$11,047 |
| Capital Expenditures | -$57 | -$136 | $0 | $0 |
| Free Cash Flow | -$22,181 | -$36,671 | -$2,381 | -$11,047 |